WO2004046113A2 - Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors - Google Patents
Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors Download PDFInfo
- Publication number
- WO2004046113A2 WO2004046113A2 PCT/US2003/036986 US0336986W WO2004046113A2 WO 2004046113 A2 WO2004046113 A2 WO 2004046113A2 US 0336986 W US0336986 W US 0336986W WO 2004046113 A2 WO2004046113 A2 WO 2004046113A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxy
- alkyl
- substituted
- pyridylmethyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates generally to the field of phosphodiesterase 4 (PDE4) enzyme inhibition. More specifically this invention relates to selective PDE4 inhibition by novel compounds, e.g., pyridine N-oxide analogs of N-substituted diarylamines, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
- novel compounds e.g., pyridine N-oxide analogs of N-substituted diarylamines
- the cyclic nucleotide specific phosphodiesterases represent a family of enzymes that catalyze the hydrolysis of various cyclic nucleoside monophosphates (including cAMP and cGMP). These cyclic nucleotides act as second messengers within cells, and as messengers, carry impulses from cell surface receptors having bound various hormones and neurotransmitters. PDEs act to regulate the level of cyclic nucleotides within cells and maintain cyclic nucleotide homeostasis by degrading such cyclic mononucleotides resulting in temiination of their messenger role.
- PDE enzymes can be grouped into eleven families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds.
- PDE 1 is stimulated by Ca 2+ /calmodulin.
- PDE 2 is cGMP-dependent, and is found in the heart and adrenals.
- PDE 3 is cGMP-dependent, and inhibition of this enzyme creates positive motropic activity.
- PDE 4 is cAMP specific, and its inhibition causes airway relaxation, antiinflarnmatory and antidepressant activity.
- PDE 5 appears to be important in regulating cGMP content in vascular smooth muscle, and therefore PDE 5 inhibitors may have cardiovascular activity. Since the PDEs possess distinct biochemical properties, it is likely that they are subject to a variety of different forms of regulation.
- PDE4 is distinguished by various kinetic properties including low Michaelis constant for cAMP and sensitivity to certain drugs.
- the PDE4 enzyme family consists of four genes, which produce 4 isoforms of the PDE4 enzyme designated PDE4A, PDE4B, PDE4C, and PDE4D [See: Wang et al., Expression, Purification, and Characterization of human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem. Biophys. Res. Comm., 234, 320-324 (1997)].
- PDE4A PDE4A
- PDE4B PDE4C
- PDE4D PDE4D
- PDE4 isoenzymes are localized in the cytosol of cells and are unassociated with any known membranous structures. PDE4 isoenzymes specifically inactivate cAMP by catalyzing its hydrolysis to adenosine 5 '-monophosphate (AMP). Regulation of cAMP activity is important in many biological processes, including inflammation and memory. Inhibitors of PDE4 isoenzymes such as rolipram, piclamilast, CDP-840 and ariflo are powerful antiinflammatory agents and therefore may be useful in treating diseases where inflammation is problematic such as asthma or arthritis. Further, rolipram improves the cognitive performance of rats and mice in learning paradigms.
- rolipram piclamilast In addition to such compounds as rolipram, xanthine derivatives such as pentoxifylline, denbufylline, and theophylline inhibit PDE4 and have received considerable attention of late for their cognition enhancing effects.
- cAMP and cGMP are second messengers that mediate cellular responses to many different hormones and neurotransmitters. Thus, therapeutically significant effects may result from PDE inhibition and the resulting increase in intracellular cAMP or cGMP in key cells, such as those located in the nervous system and elsewhere in the body.
- Rolipram previously in development as an anti-depressant, selectively inhibits the PDE4 enzyme and has become a standard agent in the classification of PDE enzyme subtypes.
- Early work in the PDE4 field focused on depression and inflammation, and has subsequently been extended to include indications such as dementia, [see "The PDE IN Family Of Calcium-Phosphodiesterases Enzymes," John A. Lowe, III, et al., Drugs of the Future 1992, 17(9):799-807 for a general review). Further clinical developments of rolipram and other first-generation PDE4 inhibitors were terminated due to the side effect profile of these compounds.
- the primary side effect in primates is emesis, while the primary side effects in rodents are testicular degranulation, weakening of vascular smooth muscle, psychotrophic effects, increased gastric acid secretion and stomach erosion.
- the present invention relates to novel compounds, e.g., pyridme N-oxide analogs of N-substituted diarylamine compounds, that inhibit PDE4 enzymes, and especially have improved side effect profiles, e.g., are relatively non-emetic, (e.g., as compared to the previously discussed prior art compounds).
- the compounds selectively inhibit PDE4 enzymes.
- the compounds of this invention at the same time facilitate entry into cells, especially cells of the nervous system.
- the present invention provides methods for synthesizing compounds with such activity and selectivity as well as methods of (and corresponding pharmaceutical compositions for) treating a patient, e.g., mammals, including humans, requiring PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated intracellular PDE 4 levels or decreased cAMP levels, e.g., involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due in part to catabolism of intracellular cAMP levels by PDE 4 enzymes, or where such memory impairment may be improved by effectively inhibiting PDE4 enzyme activity.
- a patient e.g., mammals, including humans, requiring PDE inhibition, especially PDE4 inhibition, for a disease state that involves elevated intracellular PDE 4 levels or decreased cAMP levels, e.g., involving neurological syndromes, especially those states associated with memory impairment, most especially long term memory impairment, as where such memory impairment is due in part to catabolism of intracellular cAMP levels by PDE 4 enzymes
- the compounds of the invention improve such diseases by inhibiting PDE4 enzymes at doses which do not induce emesis.
- the present invention includes nitroxide compounds of Formulas I-III:
- R 1 is alkyl having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.);
- cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof (e.g., cyclopentyl),
- cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, C ⁇ - 4 -alkyl, C ⁇ -alkoxy or combinations thereof (e.g., cyclopentylmethyl, cyclopropylmethyl, etc.),
- aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF j OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, et ylenedioxy, cyano, or combinations thereof (e.g., methylphenyl, methoxyphenyl, chlorophenyl, etc.),
- a partially unsaturated carbocyclic group having 5 to 14 carbon atoms which is unsubstituted or substituted one or more times by halogen, alkyl, alkoxy, hydroxy, nitro, cyano, oxo, or combinations thereof (e.g., cyclohexenyl, cyclohexadienyl, indanyl, tetrahydronaphthenyl, etc.),
- heterocyclic group which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, wherein the heterocyclic group is unsubstituted or substituted one or more times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof (e.g., 3-thienyl, 3- tetrahydrofuranyl, 3-pyrrolyl, etc.), or
- -C ⁇ C-, and/or one or more -CH 2 - groups are each optionally replaced by - O- or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof (e.g., pyridylethyl, pydridylpropyl, methylpiperazinylethyl, etc.);
- cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof (e.g., cyclopentyl),
- aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, OCF 3 , amino, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid, pyrrolyl, tetrazole-5-yl, 2(- heterocycle)tetrazole-5-yl (e.g., 2-(2-tetrahydropyranyl)tetrazole-5-yl), hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkyls
- R -L- tert-butyldimethylsilyloxy
- R -L- or combinations thereof (e.g., substituted or unsubstituted phenyl, naphthyl, and biphenyl, such as phenyl, methylphenyl, chlorophenyl, fluorophenyl, vinylphenyl, cyanophenyl, methylenedioxophenyl, ethylphenyl, dichlorophenyl, carboxyphenyl, ethoxycarbonylphenyl, dimethylphenyl, hydroxymethylphenyl, nitrophenyl, aminophenyl, etc.),
- heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom (preferably N, S or O), which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfmyl, alkylsulfonyl, phenoxy, trialkylsilyloxy (e.g.
- R 4 -L- tert-butyldimethylsilyloxy
- R 4 -L- or combinations thereof (e.g., pyridyl, thienyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrimidinyl, imidazolyl, thiazolyl, etc.), or
- heterocyclic group which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times by halogen, hydroxy, aryl, alkyl, alkoxy, cyano, trifluoromethyl, nitro, oxo, or combinations thereof (e.g., 3-thienyl, 3-tetrahydrofuranyl, 3-pyrrolyl, etc.);
- alkyl having 1 to 8, preferably 1 to 4 carbon atoms, which is unsubstituted or substituted one or more times by halogen, C ⁇ - 4 -alkyl, C ⁇ - 4 -alkoxy, oxo, or combinations thereof (e.g., methyl, ethyl, propyl, etc.),
- a partially unsaturated carbocycle-alkyl group wherein the carbocyclic portion has 5 to 14 carbon atoms and the alkyl portion has 1 to 5 carbon atoms, which is unsubstituted or substituted, preferably in the carbocyclic portion, one or more times by halogen, alkyl, alkoxy, nitro, cyano, oxo, or combinations thereof (e.g., cyclohexenylmethyl, etc.),
- cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkoxy, alkyl having 1 to 4 carbon atoms, or combinations thereof (e.g., cyclopentyl),
- cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, alkyl, alkoxy or combinations thereof (e.g., cyclopentylmethyl, cyclopropylmethyl, etc.),
- aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy, dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, cycloalkyl, aryl (e.g., phenyl, naphthyl, and biphenyl), heteroaryl, or combinations thereof (e.g., substituted or unsub
- arylalkyl having 7 to 19 carbon atoms, wherein the aryl portion has 6 to 14 carbon atoms and the alkyl portion, which is branched or unbranched, has
- a heterocyclic group which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof (e.g., pyridyl, thien
- heterocycle-alkyl group wherein the heterocyclic portion is saturated, partially saturated or unsaturated, and has 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, and the alkyl portion which is branched or unbranched and has 1 to 5 carbon atoms, the heterocycle-alkyl group is unsubstituted or substituted one or more times in the heterocyclic portion by halogen, alkyl, alkoxy, cyano, trifluoromethyl, CF 3 O, nitro, oxo, amino, alkylamino, dialkylamino, or combinations thereof and/or substituted in the alkyl portion by halogen, cyano, or methyl or combinations thereof (e.g., pyridylmethyl, pyridylpropyl, methylpridylmethyl, etc.);
- aryl having 6 to 14 carbon atoms and which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, arninomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, (e.g., substituted or unsubstituted phenyl and naphthyl, methylphenyl, chlorophenyl, fluorophenyl, vinylphenyl, cyanoph
- R 6 is H, halogen, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, CN, or hydroxyl;
- R 7 is H
- alkyl having 1 to 8 carbon atoms which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen, cyano, hydroxy, C ⁇ - 4 -alkoxy, or combinations thereof
- cycloalkyl having 3 to 10, preferably 3 to 8 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, oxo, cyano, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, or combinations thereof (e.g., cyclopentyl),
- cycloalkylalkyl having 4 to 16, preferably 4 to 12 carbon atoms, which is unsubstituted or substituted in the cycloalkyl portion and/or the alkyl portion one or more times by halogen, oxo, cyano, hydroxy, C ⁇ - 4 -alkyl, C ⁇ - -alkoxy or combinations thereof (e.g., cyclopentylmethyl, cyclopropylmethyl, etc.), aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, CF 3; OCF 3 , alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, cyano, or combinations thereof (e.g., methylphenyl, methoxyphenyl, chlorophenyl, etc.),
- a heterocyclic group which is saturated, partially saturated or unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is an N, O or S atom, which is unsubstituted or substituted one or more times by halogen, alkyl, hydroxy, alkoxy, alkoxyalkoxy, nitro, methylenedioxy, ethylenedioxy, trifluoromethyl, amino, aminomethyl, aminoalkyl, aminoalkoxy dialkylamino, hydroxyalkyl (e.g., hydroxymethyl), hydroxamic acid, tetrazole-5-yl, hydroxyalkoxy, carboxy, alkoxycarbonyl (e.g., tert-butyloxycarbonyl, ethoxycarbonyl), cyano, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, phenoxy, or combinations thereof (e.g., tetrahydrofuranyl,
- O- or -NH- and/or the alkyl portion is optionally substituted by halogen, oxo, hydroxy, cyano, or combinations thereof (e.g., pyridylethyl, pydridylpropyl, methylpiperazinylethyl, etc.);
- R 8 is H, or
- R 9 is alkoxy or alkylthio, in each case having 1 to 4 carbon atoms, which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen (e.g., OCH 3 , OCHF 2 , OCF 3 , etc.); R 10 is -CO-C ⁇ - -alkyl which is branched or unbranched and which is unsubstituted or substituted one or more times by halogen (e.g., CH , CHF 2 , CF 3 , etc.), or is
- R n is H or alkyl having 1 to 4 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.);
- R 12 is alkyl having 1 to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.);
- R 13 is alkyl having 1 to 6 carbon atoms, which is branched or unbranched, and which is unsubstituted or substituted one or more times by halogen (e.g., CH 3 , CHF 2 , CF 3 , etc.);
- X and Y are each independently O or S;
- G is alkylene having 2 to 7 carbon atoms which is unsubstituted or substituted one or more times by halogen;
- optically active compounds can be in the form of one of their separate enantiomers or in the form of mixtures thereof, including racemic mixtures.
- optically active compounds can be in the form of one of their separate enantiomers or in the form of mixtures thereof, including racemic mixtures.
- Corresponding compounds in which the N atom of the pyridyl ring is not in nitroxide form are disclosed in related applications Serial No. 10/051,309, filed January 22, 2002, Serial No. 60/396,726, filed July 19, 2002, and Serial No. 10/622,117, filed July 18, 2003, the entire disclosures of which are incorporated herein by reference.
- the compounds of the present invention are effective in inhibiting, or modulating the activity of PDE4 in animals, e.g., mammals, especially humans. These compounds exhibit neurological activity, especially where such activity affects cognition, including long term memory. These compounds will also be effective in treating diseases where decreased cAMP levels are involved. This includes but is not limited to inflammatory diseases. These compounds may also function as antidepressants, or be useful in treating cognitive and negative symptoms of schizophrenia.
- intermediate compounds which correspond to compounds of Formula I, wherein R 2 and R 3 are as previously defined for Formula I, but R 1 is H, tert-butyldimethylsilyl-, or a suitable phenolic protecting group.
- Suitable phenolic protecting groups are described, for example, in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis, 3 rd Edition, John Wiley & Sons, 1999, pp. 246-293.
- radio-labeled compounds such as where R 1 is 3 H 3 C-, 14 CH 3 - or ⁇ CH 3 -, for example by removing the protecting group and reacting the resultant compound in which R 1 is H with suitable radio-labelled reagents.
- radio-labeled compounds are useful for determining compound tissue distribution in animals, in PET imaging studies, and for in vivo, ex vivo, and in vitro binding studies.
- intermediate compounds which correspond to compounds of Formula I, wherein R 1 and R 3 are as previously defined for Formula I, but R 2 is H, tert- butyldimethylsilyloxy-, or a suitable phenolic protecting group.
- Suitable phenolic protecting groups are described, for example, in Greene, T.W. and Wuts, P.G.M., Protective Groups in Organic Synthesis, 3 rd Edition, John Wiley & Sons, 1999, pp. 246- 293.
- Compounds in which R 2 is H are useful as intermediates, for example, as scaffolds for parallel or combinatorial chemistry applications. Further, these compounds are useful for the introduction of radio-labels such as 3 H, 14 C, or n C.
- R 3 is H.
- Additional radio-labeled compounds that are useful for determining compound tissue distribution in animals, in PET imaging studies, and for in vivo, ex vivo, and in vitro binding studies are compounds according to Formulas I-III wherein R 3 is aryl and the aryl structure contains a 14 C atom in the ring, as well as compounds of Foraiula III in which R 9 is OCH 3 in which the C atom is l C or at least one of the H atoms is 3 H.
- Halogen herein refers to F, Cl, Br, and I. Preferred halogens are F and Cl.
- Alkyl as a group or substituent per se or as part of a group or substituent (e.g., alkylamino, trialkylsilyloxy, aminoalkyl, hydroxyalkyl), means generally a straight-chain or branched-chain aliphatic hydrocarbon radical having, for example, 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, especially 1 to 4 carbon atoms.
- Suitable alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyL undecyl, and dodecyl.
- alkyl groups include 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, 1- , 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2- ethylbutyl, ethylmethylpropyl, trimethylpropyl, methylhexyl, dimethylpentyl, ethylpentyl, ethylmethylbutyl, dimethylbutyl, and the like.
- Substituted alkyl groups are alkyl groups as described above which are substituted in one or more positions by, for example, halogens, oxo, hydroxyl, Ci ⁇ -alkoxy and or cyano.
- Halogens are preferred substituents, especially F and Cl.
- Alkoxy means alkyl-O- groups and alkoxyalkoxy means alkyl-O-alkyl-O- groups in which the alkyl portions are in accordance with the previous discussion.
- Suitable alkoxy and alkoxyalkoxy groups include methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy methoxymethoxy ethoxymethoxy, propoxymethoxy, and methoxyethoxy.
- Preferred alkoxy groups are methoxy and ethoxy.
- alkoxycarbonyl means alkyl -O-CO- in which the alkyl portion is in accordance with the previous discussion. Examples include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and tert-butoxycarbonyl.
- Cycloalkyl means a monocyclic, bicyclic or tricyclic nonaromatic saturated hydrocarbon radical having 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, especially 3 to 6 carbon atoms.
- Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, 1-decalin, adamant- 1-yl, and adamant-2-yl.
- Suitable cycloalkyl groups include spiropentyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, bicyclo[5.1.0]octyl, spiro[2.6]nonyl, bicyclo[2.2.0]hexyl, spiro[3.3]heptyl, bicyclo[4.2.0]octyl, and spiro[3.5]nonyl.
- Preferred cycloalklyl groups are cyclopropyl, cyclopentyl and cyclohexyl.
- the cycloalkyl group can be substituted, for example, substituted by halogens and/or alkyl groups.
- Cycloalkylalkyl refers to cycloalkyl-alkyl radicals in which the cycloalkyl and alkyl portions are in accordance with previous discussions. Suitable examples include cyclopropylmethyl and cyclopentylmethyl.
- Aryl as a group or substituent per se or as part of a group or substituent, refers to an aromatic carbocyclic radical containing 6 to 14 carbon atoms, preferably 6 to 12 carbon atoms, especially 6 to 10 carbon atoms.
- Suitable aryl groups include phenyl, naphthyl and biphenyl.
- Substituted aryl groups include the above-described aryl groups which are substituted one or more times by, for example, halogen, alkyl, hydroxy, alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, alkylamino, ⁇ ialkylamino, hydroxyalkyl, hydroxyalkoxy, carboxy, cyano, acyl, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, and phenoxy.
- Arylalkyl refers to an aryl-alkyl-radical in which the aryl and alkyl portions are in accordance with the previous descriptions. Suitable examples include benzyl, 1- phenethyl, 2-phenethyl, phenpropyl, phenbutyl, phenpentyl, and napthylmethyl.
- Heteroaryl refers to an aromatic heterocyclic group having one or two rings and a total number of 5 to 10 ring atoms wherein at least one of the ring atoms is a heteroatom.
- the heteroaryl group contains 1 to 3, especially 1 or 2, hetero-ring atoms which are selected from N, O and S.
- Suitable heteroaryl groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, dithialyl, oxathialyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazolyl, oxathiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, oxazinyl, isoxazinyl, oxathiazinyl, oxadiazinyl, benzofuranyl, isobenzofuranyl, thionaphthenyl, isothionaphthenyl, indolyl, isoindolyl, indazoly
- Substituted heteroaryl refers to the heteroaryl groups described above which are substitued in one or more places by, for example, halogen, aryl, alkyl, alkoxy, carboxy, methylene, cyano, trifluoromethyl, nitro, oxo, amino, alkylamino, and dialkylamino.
- Heterocycles include heteroaryl groups as described above as well as non- aromatic cyclic groups containing at least one hetero-ring atom, preferably selected from N, S and O, for example, tetrahydrofuranyl, piperidinyl, and pyrrofidinyl.
- Heterocycle-alkyl refers to a heterocycle-alkyl-group wherein the heterocyclic and alkyl portions are in accordance with the previous discussions. Suitable examples are pyridylmethyl, thienylmethyl, pyrimidinylmethyl, pyrazinylmethyl, and isoquinolinylmethyl.
- Suitable examples are cyclopentenyl, cyclohexenyl, cyclohexadienyl, tetrahydronaphthenyl and indan-2-yl.
- Suitable alkenyl groups are ethenyl, 1 -propenyl, 2-methylethenyl, 1-butene, 2- butene, 1-pentenyl, and 2-pentenyl.
- Alkynyl refers to straight-chain or branched-chain aliphatic radicals containing 2 to 12 carbon atoms in which one or more -CH 2 -CH 2 - structures are each replaced by -C ⁇ C-.
- Suitable alkynyl groups are ethynyl, propynyl, 1-butynyl, and 2-butynyl.
- Acyl refers to alkanoyl radicals having 1 to 13 carbon atoms in which the alkyl portion can be substituted by halogen, alkyl, aryl and or alkoxy, or aroyl radicals having 7 to 15 carbon atoms in which the aryl portion can be substituted by, for example, halogen, alkyl and/or alkoxy.
- Suitable acyl groups include formyl, acetyl, propionyl, butanoyl and benzoyl.
- Substituted radicals preferably have 1 to 3 substituents, especially 1 to 2 substituents.
- R 2 is preferably cycloalkyl, particularly cyclopentyl.
- R 2 is also preferably aryl or arylalkyl, particularly substituted or unsubstituted phenyl or phenylalkyl, such as phenyl, methylphenyl, methoxyphenyl, chlorophenyl, phenethyl, phenpropyl, phenbutyl, phenylethenyl, phenoxyethyl, phenoxypropyl, phenoxybutyl, chlorophenylethyl, methoxyphenylethyl, chlorophenylethenyl, chlorophenoxyethyl, chlorophenypropyl, methoxyphenpropyl, methoxyphenbutyl, chlorophenbutyl, nitrophenbutyl, cMorophenylaminoethyl, and the like.
- phenyl methylphenyl, methoxyphenyl, chlorophenyl, phenethyl, phenpropyl, phenbutyl,
- R 2 is also preferably a partially unsaturated carbocyclic groups, which is unsubstituted or substituted, particularly cyclohexenyl, cyclohexadienyl, indan-2-yl.
- R 2 is also preferably an alkyl group having 1 to 8 carbon atoms, especially 1 to 4 carbon atoms, which is substituted or unsubstituted, e.g., methyl, difluoromethyl, trifluoromethyl, and methoxyethyl.
- Preferred R 2 include cyclopentyl, tetrahydrofuranyl, CHF 2 , methoxyethyl, cyclopropylmethyl, phenethyl, phenpropyl, phenylethenyl, phenoxyethyl, phenoxybutyl, phenylaminoetliyl, indan-2-yl, pyridylethyl, and pyridylpropyl.
- R is preferably aryl or heteroaryl, especially phenyl, naphthyl, biphenyl, furanyl, pyrazinyl, pyrimidinyl, pyridyl, quinolinyl, and isoquinolinyl, which in each case is unsubstituted or is substituted one or more times.
- Preferred substituents are OH, F, Cl, CF 3 , alkyl (such as methyl or ethyl), alkoxy (such as methoxy and ethoxy), CN, vinyl, CH 2 OH, CONHOH, CONH 2 , methylenedioxy, COOH, and combinations thereof.
- R 3 is preferably pyridyl or phenyl which in each case is substituted or unsubstituted.
- R 3 can be phenyl substituted by halogen, COOH and/or CN.
- L- e.g., R 4 -, R 4 -O-, R 4 -CO-, R 4 -NH-CO-, R 4 -SO 2 -NH-, R 4 -SO 2 -NHCO-, R 4 -SO 2 -NH- alkylene-O-, NH 2 -alkyl-NH-CO-, R 4 -alkylene-NH-CO-, and alkyl-CO-NH-alkyl-.
- Other preferred substituents include methyl, ethyl, Cl, F, CN, OCH 3 , CF 3 , amino, nitro, CH 2 OH and COOH.
- R 3 is aryl substituted by R 4 -SO -NH-, it is preferably a substituted phenyl group and R 4 is preferably methyl, ethyl, propyl or phenyl.
- R 3 is aryl substituted by R 4 -SO 2 -NH-alkylene-O-, it is preferably a substituted phenyl.
- R 4 is preferably methyl, ethyl, propyl or phenyl and alkylene is preferably -CH 2 -, -CH 2 CH 2 - or -CH 2 CH 2 CH 2 -.
- R 3 is aryl substituted by R 4 -L-, it is preferably substituted phenyl.
- preferred R 4 groups include phenyl, tetrazolyl, oxazinyl, piperazinyl, methylpiperazinyl, pyridyl, methylpyridyl, pyrrolinyl, methylpyrrolinyl, piperadinyl, or methylpiperadinyl, and L is preferably a single bond, -O-, -CO-, -CH 2 -, -CH 2 CH 2 -, - CH 2 CH 2 CH 2 -, -CH2-O-, -CH 2 CH 2 -O-, -CH 2 CH2CH 2 -O-, -CH 2 -NH-CH 2 CH 2 -O-, -CO- NH-, -NH-CO-, or -CONHSO 2 -.
- R 8 is preferably H or alkyl having 1 to 4 carbon atoms, especially -C 2 H 5 .
- R 10 is preferably -CO-d. 4 -alkyl, e.g., -COCH 3 .
- R 12 and R 13 are each independently preferably -CH 3 or -CH 2 CH 3 .
- PDE4 inhibitors in accordance with the invention are compounds described by subformulas la-Ix, Ila-IIf, and Illa-IIIe which correspond, respectfively, to Formulas I-III but exhibit the following preferred groups:
- R 1 is methyl or CHF 2 ;
- R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, aryl, or heterocyclic, in each case substituted or unsubstituted; and R 3 is aryl or heteroaryl, in each case substituted or unsubstituted.
- lb R 1 is methyl or CHF 2 ;
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or tefrahydrofuranyl
- Ic R 1 is methyl or CHF 2 ;
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2-pyridylethyl), or tefrahydrofuranyl
- R 3 is aryl or heteroaryl, in each case substituted or unsubstituted.
- Id R 1 is methyl or CHF 2 ;
- R 2 is cyclopentyl; and R is substituted or unsubstituted aryl or heteroaryl.
- R 1 is methyl; R is cyclopentyl; and
- R 3 is phenyl which is substituted or unsubstituted. If R 1 is methyl;
- R 2 is cyclopentyl
- R 3 is phenyl or phenyl substituted with 1 to 3 substituents.
- Ig R 1 is methyl
- R 2 is cyclopentyl
- R 3 is phenyl, naphthyl, biphenyl, pyridyl, pyrimidinyl, thiazolyl, pyrazinyl, quinolinyl, or isoquinolinyl, in each case substituted or unsubstituted.
- J-h R 1 is methyl or CHF 2 .
- Ii R 1 is methyl or CHF 2 , and B is N-O.
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2- pyridylethyl), or tefrahydrofuranyl (particularly (3R)-tefrahydrofuranyl).
- Ik R 1 is methyl or CHF 2 , B is N-O, and
- R 3 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted.
- R is methyl or CHF
- B is N-O
- R 3 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted.
- R 3 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted.
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2- pyridylethyl), or tefrahydrofuranyl (particularly (3R)-tefrahydrofuranyl), and
- R 3 is 3-pyridyl or phenyl, which in each case is substituted or unsubstituted.
- R 1 is methyl or CHF
- R 3 is phenyl which is substituted in the 3- or 4- position.
- Iq R 1 is methyl or CHF 2 , B is N-O, and
- R 3 is phenyl which is substituted in the 3- or 4- position.
- Ir R 1 is methyl or CHF 2 ,
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2- pyridylethyl), or tefrahydrofuranyl (particularly (3R)-tefrahydrofuranyl), and R 3 is phenyl which is substituted in the 3- or 4- position.
- Is R 1 is methyl or CHF 2
- B is N-O
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2- pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tefrahydrofuranyl), and
- R 3 is phenyl which is substituted in the 3- or 4- position.
- R 3 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl, 3- ethylsulfonamido-phenyl, 3-tefrazol-5-yl-phenyl, 3-hydroxymethyl- phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4-ethylsulfonamido- phenyl, 4-tefrazol-5-yl-phenyl, or 4-hydroxymethyl-phenyl.
- R 3 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl, 3- ethylsulfonamido-phenyl, 3-tefrazol-5-yl-phenyl, 3-hydroxymethyl- phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4-ethylsulfonamido- phenyl, 4-tetrazol-5-yl-phenyl, or 4-hydroxymethyl-phenyl.
- Iv R 1 is methyl or CHF 2 ,
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2- pyridylethyl), or tetrahydrofuranyl (particularly (3R)-tefrahydrofuranyl), and R 3 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl, 3- ethylsulfonamido-phenyl, 3-tefrazol-5-yl-phenyl, 3-hydroxyrnethyl- phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4-ethylsulfonamido- phenyl, 4-tefrazol-5-yl-phenyl, or 4-hydroxymethyl-phenyl.
- Iw R 1 is methyl or CHF 2 ,
- R 2 is cyclopentyl, CHF 2 , cyclopropylmethyl, pyridylethyl (particularly 2- pyridylethyl), or tefrahydrofuranyl (particularly (3R)-tefrahydrofuranyl), and
- R 3 is 3-pyridyl, 3-COOH-phenyl, 3-Cl-phenyl, 3-cyano-phenyl, 3- ethylsulfonamido-phenyl, 3-tefrazol-5-yl-phenyl, 3-hydroxymethyl- phenyl, 3-nifro-phenyl, 4-pyridyl, 4-COOH-phenyl, 4-cyano-phenyl, 4- ethylsulfonamido-phenyl, 4-tefrazol-5-yl-phenyl, or 4-hydroxymethyl- phenyl.
- R 3 is H or is aryl or heteroaryl, in each case substituted or unsubstituted.
- R 7 is cycloalkyl
- R 7 is cycloalkyl
- lid R 7 is cyclopentyl
- R 9 is alkoxy having 1 to 4 carbon atoms;
- R 10 is COCH 3 or
- Deuterium substituted compounds can be synthesized using various methods such as described in: Dean, Dennis C; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6(10)] (2000), 110 pp. CAN 133:68895 AN 2000:473538 CAPLUS; Kabalka, George W.; Narma, Rajender S. The synthesis of radiolabeled compounds VIA organometallic intermediates. Tefrahedron (1989), 45(21), 6601-21, CODE ⁇ : TETRAB ISS ⁇ :0040-4020. CAN 112:20527 AN 1990:20527 CAPLUS; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem. (1981), 64(1-2), 9-32. CODEN: JRACBN ISSN: 0022-4081, CAN 95:76229 AN 1981:476229 CAPLUS.
- solid oral dosage forms can be used for adrninistering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.
- the compounds of the present invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
- Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
- liquid oral dosage forms can also be used for adieridging compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
- Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
- the compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
- the present invention includes methods for dealing with memory loss separate from dementia, including mild cognitive impairment (MCI) and age-related cognitive decline.
- MCI mild cognitive impairment
- the present invention includes methods of freatment for memory impairment as a result of disease.
- the invention includes methods for dealing with memory loss resulting from the use of general anesthetics, chemotherapy, radiation treatment, post-surgical trauma, and therapeutic intervention.
- the compounds may be used to treat psychiatric conditions including schizophrenia, bipolar or manic depression, major depression, and drug addiction and morphine dependence. These compounds may enhance wakefulness.
- PDE4 inhibitors can be used to raise cAMP levels and prevent neurons from undergoing apoptosis. PDE4 inhibitors are also known to be anti-inflammatory. The combination of anti-apoptotic and anti-inflammatory properties make these compounds useful to freat neurodegeneration resulting from any disease or injury, including stroke, spinal cord injury, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), and multiple systems atrophy (MSA).
- the compounds of the present invention can also be used in a method of treating patients suffering from disease states characterized by decreased NMDA function, such as schizophrenia.
- the compounds can also be used to freat psychosis characterized by elevated levels of PDE 4, for example, various forms of depression, such as manic depression, major depression, and depression associated with psychiatric and neurological disorders.
- Such disease states include: asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic and allergic contact eczema, atopic eczema,
- PDE4 inhibitors for treating asthma, chronic bronchitis, psoriasis, allergic rhinitis, and other inflammatory diseases, and for inhibiting tumor necrosis factor are known within the art. See, e.g., WO 98/58901, JP11-189577, JP 10-072415, WO 93/25517, WO 94/14742, US 5,814,651, and US 5,935,978. These references also describe assays for determining PDE4 inhibition activity, and methods for synthesizing such compounds. The entire disclosures of these documents are hereby incorporated by reference.
- PDE4 inhibitors may be used to prevent or ameliorate osteoporosis, as an antibiotic, for freatment of cardiovascular disease by mobilizing cholesterol from atherosclerotic lesions, to treat rheumatoid arthritis (RA), for long-term inhibition of mesenchymal-cell proliferation after transplantation, for freatment of urinary obstruction secondary to benign prostatic hyperplasia, for suppression of chemotaxis and reduction of invasion of colon cancer cells, for freatment of B cell chronic lymphocytic leukemia (B- CLL), for inhibition of uterine contractions, to attenuate pulmonary vascular ischemia- reperfusion injury (IRI) , for corneal hydration , for inhibition of IL-2R expression and thereby abolisliing HIV-l DNA nuclear import into memory T cells, for augmentation of glucose-induced insulin secretion, in both the prevention and freatment of colitis, and to inhibit mast cell degranulation.
- RA rheumatoid arthritis
- B- CLL B
- MJD Machado-Joseph disease
- spinocerebellar ataxia type-6 alpha la- voltage dependent calcium channel
- spinocerebellar ataxia type-7 ataxin-7
- spinal and bulbar muscular atrophy SBMA, also know as Kennedy disease (androgen receptor).
- the compounds of the present invention can be a ⁇ udinistered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the freatment of cognitive impairment and/or in the treatment of psychosis, e.g., other PDE4 inhibitors, calcium channel blockers, chloinergic drugs, adenosine receptor modulators, amphakines NMDA-R modulators, mGluR modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and glanthanamine).
- each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range.
- the compounds 2-chIoromethylpyridine N-oxide and 4-chloromethylpyridine N- oxide can be prepared in a similar manner.
- Human PDE4 was obtained from baculovirus-infected Sf9 cells that expressed the recombinant enzyme.
- the cD ⁇ A encoding hPDE-4D6 was subcloned into a baculovirus vector.
- Insect cells (Sf9) were infected with the baculovirus and cells were cultured until protein was expressed.
- the baculovirus-infected cells were lysed and the lysate was used as source of hPDE-4D6 enzyme.
- the enzyme was partially purified using a DEAE ion exchange chromatography. This procedure can be repeated using cD ⁇ A encoding other PDE-4 enzymes.
- Type 4 phosphodiesterases convert cyclic adenosine monophosphate (cAMP) to 5'- adenosine monophosphate (5'-AMP).
- Nucleotidase converts 5'-AMP to adenosine. Therefore the combined activity of PDE4 and nucleotidase converts cAMP to adenosine.
- Adenosine is readily separated from cAMP by neutral alumina columns.
- Phosphodiesterase inhibitors block the conversion of cAMP to adenosine in this assay; consequently, PDE4 inhibitors cause a decrease in adenosine.
- Cell lysates (40 ul) expressing hPDE-4D6 were combined with 50 ul of assay mix and 10 ul of inhibitors and incubated for 12 min at room temperature.
- Final concenfrations of assay components were: 0. 4 ug enzyme, lOmM Tris-HCl (pH 7.5), lOmM MgCl 2 , 3 uM cAMP, 0.002 U 5 '-nucleotidase, and 3 x 10 4 cpm of [3H]cAMP.
- the reaction was stopped by adding 100 ⁇ l of boiling 5mN HC1. An aliquot of 75 ⁇ l of reaction mixture was transferred from each well to alumina columns (Multiplate; Millipore).
- test compounds are dissolved in 100% DMSO and diluted into the assay such that the final concenfration of DMSO is 0.1%. DMSO does not affect enzyme activity at this concentration.
- IC 50 values for the preferred compounds of the invention are less than 1000 nM, especially less thn 100 nM.
- the apparatus (Model E10-16SC, Coulbourn Instruments, Allentown, PA) consisted of a two-compartment chamber with an illuminated compartment connected to a darkened compartment by a guillotine door.
- the floor of the darkened compartment consisted of stainless steel rods through which an electric foot-shock could be delivered from a constant current source. All experimental groups were first habituated to the apparatus the day before the start of the experiment.
- Rats Male Spraque-Dawley (Harlan) weighing 250 to 350 g were placed in the eight-arm radial maze (each arm was 60x10x12 cm high; the maze was elevated 70 cm above the floor) for acclimation for two days. Rats were then placed individually in the center of the maze for 5 minutes with food pellets placed close to the food wells, and then, the next day, in the wells at the end of the arms; 2 sessions a day were conducted. Next, four randomly selected arms were then baited with one pellet of food each.
- the rat was restricted to the center platform (26 cm in diameter) for 15 seconds and then allowed to move freely throughout the maze until it collected all pellets of food or 10 minutes passed, whichever came first.
- Four parameters were recorded: 1) working memory errors, i.e., entries into baited arms that had already been visited during the same trial; 2) reference memory errors, i.e., entries into unbaited arms; 3) total arm entries; and 4) the test duration (seconds), i.e., the time spent in the collection of all the pellets in the maze. If the working memory error was zero and the average reference memory error was less than one in five successive trials, the rats began the drug tests. MK-801 or saline was injected 15 minutes prior to vehicle or test agent, which was given 45 minutes before the test. Experiments were performed in a lighted room, which contained several extra-maze visual cues.
- MK-801 0.1 mg/kg, i.p.
- MK-801 increased the frequencies of both working and reference memory errors (p ⁇ 0.01). This amnesic effect of MK-801 on working memory is reversed in a statistically significant manner by the adminisfration of actual test compounds in a dose- dependent fashion.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03786857A EP1569908B1 (en) | 2002-11-19 | 2003-11-19 | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
CA002506297A CA2506297A1 (en) | 2002-11-19 | 2003-11-19 | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
DE60334243T DE60334243D1 (en) | 2002-11-19 | 2003-11-19 | PYRIDINE N-OXIDE COMPOUNDS ALSPHOSPHODIESTERASE-4-INHIBITORS |
BR0315705-9A BR0315705A (en) | 2002-11-19 | 2003-11-19 | Phosphodiesterase-4 Inhibitors |
JP2004553941A JP2006508987A (en) | 2002-11-19 | 2003-11-19 | Phosphodiesterase 4 inhibitor |
NZ540138A NZ540138A (en) | 2002-11-19 | 2003-11-19 | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
MXPA05005345A MXPA05005345A (en) | 2002-11-19 | 2003-11-19 | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors. |
AT03786857T ATE481387T1 (en) | 2002-11-19 | 2003-11-19 | PYRIDINE N-OXIDE COMPOUNDS ALSPHOSPHODIESTERASE-4 INHIBITORS |
AU2003295656A AU2003295656B2 (en) | 2002-11-19 | 2003-11-19 | Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors |
NO20052976A NO20052976L (en) | 2002-11-19 | 2005-06-17 | Phosphodiesterase-4 inhibitors. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42722102P | 2002-11-19 | 2002-11-19 | |
US60/427,221 | 2002-11-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004046113A2 true WO2004046113A2 (en) | 2004-06-03 |
WO2004046113A3 WO2004046113A3 (en) | 2005-03-24 |
Family
ID=32326501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/036986 WO2004046113A2 (en) | 2002-11-19 | 2003-11-19 | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
Country Status (16)
Country | Link |
---|---|
US (3) | US7087625B2 (en) |
EP (1) | EP1569908B1 (en) |
JP (1) | JP2006508987A (en) |
KR (1) | KR20050075430A (en) |
CN (1) | CN100513397C (en) |
AT (1) | ATE481387T1 (en) |
AU (1) | AU2003295656B2 (en) |
BR (1) | BR0315705A (en) |
CA (1) | CA2506297A1 (en) |
DE (1) | DE60334243D1 (en) |
MX (1) | MXPA05005345A (en) |
NO (1) | NO20052976L (en) |
NZ (1) | NZ540138A (en) |
RU (1) | RU2356893C2 (en) |
WO (1) | WO2004046113A2 (en) |
ZA (1) | ZA200503995B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008543781A (en) * | 2005-06-10 | 2008-12-04 | メモリー・ファーマシューティカルズ・コーポレイション | Phosphodiesterase 4 inhibitor |
EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153871B2 (en) * | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
US20030149052A1 (en) * | 2002-01-22 | 2003-08-07 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
DE60325984D1 (en) | 2002-07-19 | 2009-03-12 | Memory Pharmaceutical Corp | 4-AMINOBENZOFURAN COMPOUNDS AS PHOSPHODIESTERASE-4 INHIBITORS |
CA2492907A1 (en) * | 2002-07-19 | 2004-01-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
WO2004030635A2 (en) * | 2002-10-03 | 2004-04-15 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
ES2211344B1 (en) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
US20090048255A1 (en) * | 2003-07-21 | 2009-02-19 | Schumacher Richard A | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
NZ588139A (en) | 2004-04-08 | 2012-02-24 | Targegen Inc | 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives |
ES2251866B1 (en) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
ES2251867B1 (en) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
EP1799656A4 (en) | 2004-08-25 | 2009-09-02 | Targegen Inc | Heterocyclic compounds and methods of use |
WO2008105386A1 (en) * | 2007-02-27 | 2008-09-04 | National University Corporation Okayama University | Rexinoid compound having alkoxy group |
ES2320954B1 (en) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | NEW PREPARATION PROCEDURE FOR 3-METHYL-4-PHENYLISOXAZOLO (3,4-D) IRIDAZIN-7 (6H) -ONA. |
AR066016A1 (en) * | 2007-04-11 | 2009-07-15 | Alcon Res Ltd | USE OF AN ALFA TNF INHIBITOR TOGETHER WITH AN ANTIHISTAMINE TO TREAT ALLERGIC RHINITIS AND ALLERGIC CONJUNCTIVITIS |
US20090182035A1 (en) * | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
WO2009067607A2 (en) * | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
EP2110375A1 (en) * | 2008-04-14 | 2009-10-21 | CHIESI FARMACEUTICI S.p.A. | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class |
US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
WO2010041449A1 (en) * | 2008-10-09 | 2010-04-15 | 国立大学法人 岡山大学 | Anti-allergic agent comprising rxr agonist as active ingredient |
CA2773483A1 (en) * | 2009-10-01 | 2011-04-07 | Alcon Research, Ltd. | Olopatadine compositions and uses thereof |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
NZ711587A (en) | 2013-03-14 | 2017-02-24 | Dart Neuroscience (Cayman) Ltd | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025517A1 (en) | 1992-06-15 | 1993-12-23 | Celltech Limited | Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors |
JPH1072415A (en) | 1996-06-26 | 1998-03-17 | Nikken Chem Co Ltd | 3-anilino-2-cycloalkenone derivative |
US5846514A (en) | 1994-03-25 | 1998-12-08 | Isotechnika, Inc. | Enhancement of the efficacy of nifedipine by deuteration |
US6136821A (en) | 1996-10-28 | 2000-10-24 | Novartis Ag | Naphthyridine derivatives |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698711A (en) | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
US5935978A (en) | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
GB9311281D0 (en) | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
US6096768A (en) | 1992-01-28 | 2000-08-01 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
PT652868E (en) | 1992-07-28 | 2005-01-31 | Aventis Pharma Ltd | AMP CYCLIC PHOSPHODIESTERASE INHIBITORS |
US5679696A (en) | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
TW263495B (en) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
AU6971894A (en) | 1993-05-27 | 1994-12-20 | Smithkline Beecham Laboratoires Pharmaceutiques | Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines |
EP0706513B1 (en) | 1993-07-02 | 2002-05-15 | Byk Gulden Lomberg Chemische Fabrik GmbH | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
GB9315595D0 (en) * | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
WO1995017399A1 (en) | 1993-12-22 | 1995-06-29 | Celltech Therapeutics Limited | Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors |
GB9326699D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
US5591776A (en) | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
FR2729142A1 (en) | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | New heterocyclic amine derivs. |
US5731477A (en) | 1995-01-31 | 1998-03-24 | Smithkline Beecham Corporation | Method for synthesis of aryl difluoromethyl ethers |
WO1996036611A1 (en) | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
IT1275433B (en) | 1995-05-19 | 1997-08-07 | Smithkline Beecham Farma | DIARYLDIAMINE DERIVATIVES |
FR2735777B1 (en) | 1995-06-21 | 1997-09-12 | Sanofi Sa | 4-PHENYLAMINOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP0873311A1 (en) * | 1995-12-15 | 1998-10-28 | Merck Frosst Canada Inc. | Tri-aryl ethane derivatives as pde iv inhibitors |
GB9603723D0 (en) | 1996-02-22 | 1996-04-24 | Merck & Co Inc | Diphenyl pyridyl derivatives as pde iv inhibitors |
US5710170A (en) | 1995-12-15 | 1998-01-20 | Merck Frosst Canada, Inc. | Tri-aryl ethane derivatives as PDE IV inhibitors |
GB9526246D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526243D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
AU3102697A (en) * | 1996-06-19 | 1998-01-07 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
SK176598A3 (en) | 1996-06-25 | 2000-06-12 | Pfizer | Indazole derivatives, pharmaceutical composition on their base and methods of treatment |
IL128642A0 (en) | 1996-09-04 | 2000-01-31 | Pfizer | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
CA2295106C (en) | 1997-06-24 | 2007-03-13 | Nikken Chemicals Co., Ltd. | 3-anilino-2-cycloalkenone derivatives |
TW374919B (en) * | 1997-08-28 | 1999-11-21 | Hitachi Ltd | Synchronous memory unit |
US5919937A (en) | 1997-10-29 | 1999-07-06 | Merck & Co., Inc. | Process for phosphodiesterase IV inhibitors |
PT1045690E (en) | 1997-11-25 | 2003-08-29 | Warner Lambert Co | PDE-IV INHIBITOR BENZENOSULFONAMIDES AND ITS THERAPEUTIC USE |
JP4754068B2 (en) | 1997-12-24 | 2011-08-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 4- [Aryl (piperidin-4-yl)] aminobenzamides binding to δ-opioid receptor |
JP3542482B2 (en) | 1997-12-25 | 2004-07-14 | 日研化学株式会社 | 3-anilino-2-cycloalkenone derivatives |
WO1999040085A1 (en) * | 1998-02-09 | 1999-08-12 | Darwin Discovery Limited | Benzofuran-4-carboxamides and their therapeutic use |
CA2364653A1 (en) * | 1999-02-25 | 2000-08-31 | Merck Frosst Canada & Co. | Pde iv inhibiting compounds, compositions and methods of treatment |
US6180650B1 (en) | 1999-04-23 | 2001-01-30 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE 4 inhibitors |
US6200993B1 (en) | 1999-05-05 | 2001-03-13 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE4 inhibitors |
GB2350110A (en) | 1999-05-17 | 2000-11-22 | Bayer Ag | Pharmaceutically active benzofurans |
ES2258459T3 (en) | 1999-05-21 | 2006-09-01 | Bristol-Myers Squibb Company | PINROLOTRIAZINAS INHIBIDORAS DE QUINASAS. |
JP4434362B2 (en) | 1999-06-28 | 2010-03-17 | 興和創薬株式会社 | Phosphodiesterase inhibitor |
ATE312808T1 (en) * | 1999-12-18 | 2005-12-15 | Wella Ag | 2-AMINOALKYL-1,4-DIAMINOBENZENE DERIVATIVES AND DYES CONTAINING THESE COMPOUNDS |
MY123585A (en) * | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
AU2001261962B2 (en) * | 2000-05-25 | 2005-04-21 | Merck Frosst Canada Ltd | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
KR100847169B1 (en) | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | Pyrimidineamines as angiogenesis modulators |
US6699890B2 (en) | 2000-12-22 | 2004-03-02 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
YU57603A (en) * | 2001-01-22 | 2006-08-17 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
CA2492907A1 (en) * | 2002-07-19 | 2004-01-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
-
2003
- 2003-11-19 EP EP03786857A patent/EP1569908B1/en not_active Expired - Lifetime
- 2003-11-19 CA CA002506297A patent/CA2506297A1/en not_active Abandoned
- 2003-11-19 WO PCT/US2003/036986 patent/WO2004046113A2/en active Application Filing
- 2003-11-19 MX MXPA05005345A patent/MXPA05005345A/en active IP Right Grant
- 2003-11-19 RU RU2005119627/04A patent/RU2356893C2/en not_active IP Right Cessation
- 2003-11-19 DE DE60334243T patent/DE60334243D1/en not_active Expired - Lifetime
- 2003-11-19 KR KR1020057008915A patent/KR20050075430A/en not_active Application Discontinuation
- 2003-11-19 CN CNB2003801036392A patent/CN100513397C/en not_active Expired - Fee Related
- 2003-11-19 NZ NZ540138A patent/NZ540138A/en not_active IP Right Cessation
- 2003-11-19 AU AU2003295656A patent/AU2003295656B2/en not_active Expired - Fee Related
- 2003-11-19 US US10/715,819 patent/US7087625B2/en not_active Expired - Fee Related
- 2003-11-19 JP JP2004553941A patent/JP2006508987A/en not_active Ceased
- 2003-11-19 AT AT03786857T patent/ATE481387T1/en not_active IP Right Cessation
- 2003-11-19 BR BR0315705-9A patent/BR0315705A/en not_active Application Discontinuation
-
2005
- 2005-05-18 ZA ZA200503995A patent/ZA200503995B/en unknown
- 2005-06-17 NO NO20052976A patent/NO20052976L/en unknown
-
2006
- 2006-03-20 US US11/378,615 patent/US7700631B2/en not_active Expired - Fee Related
-
2010
- 2010-03-16 US US12/724,750 patent/US20100173942A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025517A1 (en) | 1992-06-15 | 1993-12-23 | Celltech Limited | Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors |
US5846514A (en) | 1994-03-25 | 1998-12-08 | Isotechnika, Inc. | Enhancement of the efficacy of nifedipine by deuteration |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
JPH1072415A (en) | 1996-06-26 | 1998-03-17 | Nikken Chem Co Ltd | 3-anilino-2-cycloalkenone derivative |
US6136821A (en) | 1996-10-28 | 2000-10-24 | Novartis Ag | Naphthyridine derivatives |
Non-Patent Citations (12)
Title |
---|
"Curr., Pharm. Des.", vol. 6, 2000, article "Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development", pages: 10 |
"Curr., Pharm. Des., 2000", vol. 6, 2000, article "Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development.", pages: 110 |
"Handbook of Pharmaceutical Excipients", AMERICAN PHANNACEUTICAL ASSOCIATION |
"Handbook of Pharmaceutical Excipients", AMERICAN PHARMACEUTICAL ASSOCIATION |
"Pharmaceutical Dosage Forms: Tablets", MARCEL DEKKER, INC. |
"Remington's Pharmaceutical Sciences", pages: 1553 - 1593 |
EVANS, E. ANTHONY.: "Synthesis ofradiolabeled compounds", J. RADIOANAL. CHEM., vol. 64, no. 1-2, 1981, pages 9 - 32 |
GREENE, T.W.; WUTS, P.G.M.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, pages: 246 - 293 |
JOHN A. LOWE, 1111 ET AL.: "The PDE IV Family Of Calcium-Phosphodiesterases Enzymes", DRUGS OF THE FUTURE, vol. 17, no. 9, 1992, pages 799 - 807 |
KABALKA, GEORGE W.; VARMA, RAJENDER S.: "The synthesis ofradiolabeled compounds VIA organometallic intermediates", TETRAHEDRON, vol. 45, no. 21, 1989, pages 6601 - 21 |
ZHANG, H.-T. ET AL., NENROPSYCHOPHARMACOLOGY, vol. 23, 2000, pages 198 - 204 |
ZHANG, H.-T. ET AL., NEUROPSYCHOPHARMACOLOGY, vol. 23, 2000, pages 198 - 204 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008543781A (en) * | 2005-06-10 | 2008-12-04 | メモリー・ファーマシューティカルズ・コーポレイション | Phosphodiesterase 4 inhibitor |
EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
WO2009077068A1 (en) | 2007-12-14 | 2009-06-25 | Chiesi Farmaceutici S.P.A. | Ester derivatives as phosphodiesterase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
NO20052976L (en) | 2005-08-18 |
CN100513397C (en) | 2009-07-15 |
MXPA05005345A (en) | 2005-08-26 |
WO2004046113A3 (en) | 2005-03-24 |
EP1569908A2 (en) | 2005-09-07 |
EP1569908B1 (en) | 2010-09-15 |
US7087625B2 (en) | 2006-08-08 |
ZA200503995B (en) | 2006-08-30 |
CA2506297A1 (en) | 2004-06-03 |
AU2003295656A2 (en) | 2005-06-30 |
BR0315705A (en) | 2005-09-06 |
RU2005119627A (en) | 2006-01-27 |
AU2003295656A1 (en) | 2004-06-15 |
US20040152902A1 (en) | 2004-08-05 |
CN1714081A (en) | 2005-12-28 |
US20100173942A1 (en) | 2010-07-08 |
RU2356893C2 (en) | 2009-05-27 |
DE60334243D1 (en) | 2010-10-28 |
NZ540138A (en) | 2008-07-31 |
US20060211865A1 (en) | 2006-09-21 |
AU2003295656B2 (en) | 2010-11-11 |
ATE481387T1 (en) | 2010-10-15 |
US7700631B2 (en) | 2010-04-20 |
JP2006508987A (en) | 2006-03-16 |
NO20052976D0 (en) | 2005-06-17 |
KR20050075430A (en) | 2005-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7700631B2 (en) | Phosphodiesterase 4 inhibitors | |
EP1692109B1 (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
AU2002303078B2 (en) | Aniline derivatives useful as phosphodiesterase 4 inhibitors | |
EP1435944B1 (en) | 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes | |
AU2002303078A1 (en) | Aniline derivatives useful as phosphodiesterase 4 inhibitors | |
US7655802B2 (en) | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs | |
US6699890B2 (en) | Phosphodiesterase 4 inhibitors | |
US7205320B2 (en) | Phosphodiesterase 4 inhibitors | |
US20030149052A1 (en) | Phosphodiesterase 4 inhibitors | |
US7153871B2 (en) | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs | |
NZ547469A (en) | 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1971/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 168593 Country of ref document: IL Ref document number: 2506297 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/03995 Country of ref document: ZA Ref document number: 540138 Country of ref document: NZ Ref document number: 1020057008915 Country of ref document: KR Ref document number: 200503995 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004553941 Country of ref document: JP Ref document number: 20038A36392 Country of ref document: CN Ref document number: 1-2005-500952 Country of ref document: PH Ref document number: PA/a/2005/005345 Country of ref document: MX Ref document number: 2003786857 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003295656 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05057518 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2005119627 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057008915 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003786857 Country of ref document: EP |